127 related articles for article (PubMed ID: 37927142)
1. SGLT2 is upregulated to acquire cisplatin resistance and SGLT2 inhibition reduces cisplatin resistance in hepatoblastoma.
Fujiyoshi S; Honda S; Ara M; Kondo T; Kobayashi N; Taketomi A
J Hepatobiliary Pancreat Sci; 2024 Apr; 31(4):223-233. PubMed ID: 37927142
[TBL] [Abstract][Full Text] [Related]
2. Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, with Dapagliflozin and Ipragliflozin.
Choi MK; Nam SJ; Ji HY; Park MJ; Choi JS; Song IS
Pharmaceutics; 2020 Mar; 12(3):. PubMed ID: 32183468
[TBL] [Abstract][Full Text] [Related]
3. Dapagliflozin Inhibits Cell Adhesion to Collagen I and IV and Increases Ectodomain Proteolytic Cleavage of DDR1 by Increasing ADAM10 Activity.
Okada J; Yamada E; Saito T; Yokoo H; Osaki A; Shimoda Y; Ozawa A; Nakajima Y; Pessin JE; Okada S; Yamada M
Molecules; 2020 Jan; 25(3):. PubMed ID: 31979355
[TBL] [Abstract][Full Text] [Related]
4. Development of a drug resistance model for hepatoblastoma.
Eicher C; Dewerth A; Kirchner B; Warmann SW; Fuchs J; Armeanu-Ebinger S
Int J Oncol; 2011 Feb; 38(2):447-54. PubMed ID: 21132272
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cIAP1 in the effective suppression of chemotherapy‑resistant hepatoblastoma.
Tsukada R; Nomura M; Ueno T; Okuyama H
Oncol Rep; 2022 Apr; 47(4):. PubMed ID: 35211761
[TBL] [Abstract][Full Text] [Related]
6. Hypermethylation of CSF3R is a novel cisplatin resistance marker and predictor of response to postoperative chemotherapy in hepatoblastoma.
Fujiyoshi S; Honda S; Minato M; Ara M; Suzuki H; Hiyama E; Taketomi A
Hepatol Res; 2020 May; 50(5):598-606. PubMed ID: 31894653
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma.
Yu Y; Zhao X; Zhang Y; Kang Y; Wang J; Liu Y
Oncol Rep; 2015 Jul; 34(1):407-14. PubMed ID: 25955434
[TBL] [Abstract][Full Text] [Related]
8. A sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin comparison with insulin shows important effects on Zn
Olgar Y; Turan B
Can J Physiol Pharmacol; 2019 Jun; 97(6):528-535. PubMed ID: 30444646
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor/heme oxygenase-1 axis is involved in chemoresistance to cisplatin and pirarubicin in HepG2 cell lines and hepatoblastoma specimens.
Kobayashi T; Kubota M; Kinoshita Y; Arai Y; Oyama T; Yokota N; Saito K; Matsuda Y; Osawa M
Pediatr Surg Int; 2019 Dec; 35(12):1369-1378. PubMed ID: 31559456
[TBL] [Abstract][Full Text] [Related]
10. PIM447 inhibits oncogenesis and potentiates cisplatin effects in hepatoblastoma.
Wadhwani N; Markert HR; Marayati R; Bownes LV; Quinn CH; Aye JM; Stewart JE; Yoon KJ; Beierle EA
J Pediatr Surg; 2021 Jun; 56(6):1157-1164. PubMed ID: 33762119
[TBL] [Abstract][Full Text] [Related]
11. PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma.
Marayati R; Stafman LL; Williams AP; Bownes LV; Quinn CH; Aye JM; Stewart JE; Yoon KJ; Anderson JC; Willey CD; Beierle EA
Sci Rep; 2021 Mar; 11(1):5984. PubMed ID: 33727604
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma.
Kuang H; Liao L; Chen H; Kang Q; Shu X; Wang Y
Med Sci Monit; 2017 Aug; 23():3737-3745. PubMed ID: 28763435
[TBL] [Abstract][Full Text] [Related]
13. Sodium glucose co-transporter 2 inhibition reduces succinate levels in diabetic mice.
Herat LY; Ward NC; Magno AL; Rakoczy EP; Kiuchi MG; Schlaich MP; Matthews VB
World J Gastroenterol; 2020 Jun; 26(23):3225-3235. PubMed ID: 32684737
[TBL] [Abstract][Full Text] [Related]
14. Exploring the Role of Sodium-Glucose Cotransporter as a New Target for Cancer Therapy.
Bardaweel S; Issa A
J Pharm Pharm Sci; 2022; 25():253-265. PubMed ID: 35977549
[TBL] [Abstract][Full Text] [Related]
15. Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity.
Yoshii A; Nagoshi T; Kashiwagi Y; Kimura H; Tanaka Y; Oi Y; Ito K; Yoshino T; Tanaka TD; Yoshimura M
Cardiovasc Diabetol; 2019 Jul; 18(1):85. PubMed ID: 31262297
[TBL] [Abstract][Full Text] [Related]
16. Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway.
Zhou J; Zhu J; Yu SJ; Ma HL; Chen J; Ding XF; Chen G; Liang Y; Zhang Q
Biomed Pharmacother; 2020 Dec; 132():110821. PubMed ID: 33068934
[TBL] [Abstract][Full Text] [Related]
17. Sodium-glucose cotransporter 2 inhibition does not improve the acute pressure natriuresis response in rats with type 1 diabetes.
Jones NK; Costello HM; Monaghan MT; Stewart K; Binnie D; Marks J; Bailey MA; Culshaw GJ
Exp Physiol; 2023 Mar; 108(3):480-490. PubMed ID: 36644793
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis.
Chun HJ; Kim ER; Lee M; Choi DH; Kim SH; Shin E; Kim JH; Cho JW; Han DH; Cha BS; Lee YH
Metabolism; 2023 Aug; 145():155612. PubMed ID: 37277060
[TBL] [Abstract][Full Text] [Related]
19. Determining the Role of SGLT2 Inhibition with Dapagliflozin in the Development of Diabetic Retinopathy.
Herat LY; Matthews JR; Ong WE; Rakoczy EP; Schlaich MP; Matthews VB
Front Biosci (Landmark Ed); 2022 Dec; 27(12):321. PubMed ID: 36624945
[TBL] [Abstract][Full Text] [Related]
20. Central administration of sodium-glucose cotransporter-2 inhibitors increases food intake involving adenosine monophosphate-activated protein kinase phosphorylation in the lateral hypothalamus in healthy rats.
Takeda K; Ono H; Ishikawa K; Ohno T; Kumagai J; Ochiai H; Matumoto A; Yokoh H; Maezawa Y; Yokote K
BMJ Open Diabetes Res Care; 2021 Apr; 9(1):. PubMed ID: 33879516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
